SCHEMBL10070549

SCHEMBL10070549

Cc1ccc(OC(=O)N2CCC(c3nc(-c4ccc(F)cc4)n[nH]3)CC2)c(C)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 3/20 0.44
P2RY12 Q9H244 1/20 0.41
PDK2 Q15119 3/20 0.40
HSD11B1 P28845 1/20 0.40
HTR2B P41595 1/20 0.40
TLR9 Q9NR96 2/20 0.40
TLR8 Q9NR97 2/20 0.40
TLR7 Q9NYK1 2/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
TRPC3 Q13507 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TRPC7 Q9HCX4 1/20 0.39
AKT1 P31749 2/20 0.37
AKT2 P31751 2/20 0.37
KCNH2 Q12809 1/20 0.37
MAPK11 Q15759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10070083 0.92 P2RY12 (0.40) KITP2RY12HSD11B1TLR9TLR8
SCHEMBL10069718 0.89 CPT1A (0.45) KITP2RY12HSD11B1TLR9TLR8
SCHEMBL10070076 0.88 KIT (0.44) KITP2RY12PDK2HSD11B1HTR2B
SCHEMBL10070075 0.85 CPT2 (0.45) P2RY12HSD11B1TP53AKT1AKT2
SCHEMBL1653319 0.84 KIT (0.46) KITP2RY12PDK2HTR2BTLR9
SCHEMBL10040557 0.81 LMNA (0.55) HSD11B1LMNAHTT
SCHEMBL10070550 0.81 CPT1A (0.40) KITP2RY12HSD11B1HTR2BTLR9
SCHEMBL10069708 0.80 HPGDS (0.52) KITPDK2KDM4EHTT
SCHEMBL10070539 0.80 P2RY12 (0.47) P2RY12HSD11B1HTR2BGPR119MGLL
SCHEMBL10070552 0.80 HTR2B (0.43) P2RY12HSD11B1HTR2BTLR9TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207199-B2 Azole compound ASTELLAS PHARMA INC. (JP) 2012-06-26 US disclosed
US-20110118311-A1 AZOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-05-19 US disclosed
WO-2010007966-A1 AZOLE COMPOUND アステラス製薬株式会社 (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118311-A1 AZOLE COMPOUND FAAH, FAAH2, TRPV1 KIT 681/4885P2RY12 139/4885PDK2 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.